查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401785

血红蛋白病市场，按类型、治疗、配销通路、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Hemoglobinopathies Market, By Type, By Therapy, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 298 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022 年血红素病市场规模为 84.28 亿美元，2023 年至 2030 年复合CAGR为 12.5%。

血红素病市场-市场动态

发展中国家和低收入国家血红素病患病率不断上升，推动了市场成长

血红蛋白疾病，包括镰状细胞疾病和地中海贫血，是可以预防的遗传性疾病。严重时，它们与慢性、危及生命和损害生命的疾病有关，具有重大健康风险，可能导致死亡或残疾。不幸的是，由于缺乏知识、全面的计划和有组织的预防措施，全世界很大一部分儿童出生时就患有这些疾病。根据华大基因2023年全球基因组报告，全球有5.2%的人患有血红蛋白异常，这导致每年有30万至40万婴儿出生时患有严重的血红蛋白疾病。此外，每 10,000 名活产儿中就有 4.4 人患有地中海贫血，这是一种遗传性血红蛋白病，在地中海沿岸地区、非洲、中东、东南亚和中国南部最为常见。大约 80% 的地中海贫血病例发生在低收入和中等收入国家，这些国家的患者的生活品质更有可能因获得医疗服务的机会不平等而受到​​威胁。控制地中海贫血的计画必须包括遗传咨询、筛检、公众意识和产前诊断。考虑到问题的严重性和管理成本的影响，需要立即采取适当的控制措施。

血红蛋白病市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2023-2030 年）每年将以 12.5% 左右的CAGR成长

根据类型细分，镰状细胞疾病细分市场预计将在预测期内主导市场

从地区来看，预计北美在预测期内将主导市场

血红素病市场細項分析：

全球血红蛋白病市场根据类型、治疗、配销通路和区域进行细分。

根据类型，全球市场分为镰状细胞疾病、地中海贫血等。镰状细胞疾病预计将在预测期内主导市场。镰状细胞疾病诊断市场最近出现了一些显着的发展。新型诊断技术的创造和采用就是这样的趋势之一。现代基因检测技术，包括次世代定序和分子诊断，使得更准确、更有效地识别镰状细胞疾病及其变异成为可能。快速诊断套件和即时检测 (POCT) 设备也已开发出来，使各种医疗保健环境中的筛检变得快速、轻鬆。例如，Molbio Diagnostics 和 ShanMukha Innovations 于 2023 年 5 月合作，创建、开发和销售价格实惠的床边诊断工具，用于诊断与血红蛋白疾病相关的疾病。

根据治疗方法，全球血红素病产业分为ACE抑制剂、单株抗体药物、羟基脲等。

根据配销通路，市场分为线上提供者、医院药房、药局和零售药房。

血红素病市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。这些区域根据开展业务的国家进一步划分。预计北美将在预测期内主导市场，因为医疗保健设施越来越好，人们对血红蛋白病的认识也越来越高。不同的团体进行不同的活动来提高意识。例如，美国国家组织 SCDAA 透过提高意识和提供支持来倡导镰状细胞疾病患者及其家人的利益。为了提高人们对这种疾病的认识并改善他们的生活，他们安排活动、提供资源并提供指导材料。由于政府机构和研究机构推出了多项支持血红蛋白病新疗法开发的计划，预计该地区的市场将会成长。

血红素病市场-竞争格局：

为了增加市场份额，企业领导者正在采取多种措施，包括建立伙伴关係、协作、併购以及密集研发。市场上的主要参与者包括诺华公司、新基公司、蓝鸟生物公司、Emmaus Life Sciences Inc.、辉瑞公司、Sangamo Therapeutics, Inc.、Prolong Pharmaceuticals, LLC、Global Blood Therapeutics, Inc.、Gamida Cell 和Bioverativ公司

最近的发展：

2023年8月，美国FDA解除了FTX-6058新药临床试验（IND）申请的临床搁置，可用于治疗镰状细胞疾病（SCD）。 Fulcrum Therapeutics, Inc. 是一家临床阶段的生物製药公司，优先考虑改善患有基因罕见疾病的患者的生活。

目录

第一章：血红蛋白病市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按类型分類的血红蛋白病市场片段
    • 血红素病治疗市场片段
    • 按配销通路分類的血红蛋白病市场片段
    • 按国家/地区分類的血红素病市场片段
    • 按地区分類的血红素病市场片段
  • 竞争洞察

第 3 章：血红蛋白疾病主要市场趋势

  • 血红素病市场驱动因素
    • 市场驱动因素的影响分析
  • 血红素病市场限制
    • 市场限制影响分析
  • 血红素病市场机会
  • 血红素病市场未来趋势

第 4 章：血红蛋白病产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：血红素病市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：血红素病市场格局

  • 2022 年血红素病市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：血红蛋白疾病市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 镰形血球贫血症
    • 地中海型贫血
    • 其他的

第 8 章：血红蛋白疾病市场 - 按治疗

  • 概述
    • 按疗法分類的细分市场份额分析
    • ACE抑制剂
    • 单株抗体药物
    • 羟基脲
    • 其他的

第 9 章：血红蛋白病市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 线上提供者
    • 医院药房
    • 药局
    • 零售药房

第 10 章：血红蛋白疾病市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美血红素病主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按类型）
    • 北美市场规模和预测（按治疗）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲血红素病主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模与预测（按治疗）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区血红素病主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模与预测（按治疗）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲血红蛋白病主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模与预测（按疗法）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲血红蛋白病主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按类型）
    • 中东和非洲市场规模和预测（按疗法）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 血红素病产业

  • 竞争仪表板
  • 公司简介
    • Novartis AG
    • Celgene Corporation
    • bluebird bio, Inc.
    • Emmaus Life Sciences Inc.
    • Pfizer, Inc.
    • Sangamo Therapeutics, Inc.
    • Prolong Pharmaceuticals, LLC
    • Global Blood Therapeutics, Inc.
    • Gamida Cell
    • Bioverativ Inc.

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV1986

REPORT HIGHLIGHT

Hemoglobinopathies Market size was valued at USD 8,428 Million in 2022, expanding at a CAGR of 12.5% from 2023 to 2030.

Hemoglobinopathy diagnosis and treatment are becoming more and more common due to the growing demand for newborn screening programs and the diagnosis of prenatal hemoglobin abnormalities. This is particularly critical in poorer countries where screening and awareness initiatives are only getting underway. Additionally, it is anticipated that growing patient and healthcare professional awareness of the need for early diagnosis and treatment will propel market revenue growth. This is particularly true in the case of sickle cell anemia when early detection and treatment can significantly improve patient outcomes and reduce healthcare costs. However, a significant factor that can limit market revenue development is the high cost of treatment, particularly for gene therapy and stem cell transplants. Moreover, severe legislative limitations, and a lack of access to healthcare in developing countries, especially for those in need of specialized treatment, are increasing the prevalence of hemoglobinopathies worldwide.

Hemoglobinopathies Market- Market Dynamics

Increasing prevalence of hemoglobinopathies in developing and low-income countries boosting the market growth

Haemoglobinopathies, including sickle cell disease and Thalassemia, are hereditary conditions that can be prevented. In their severe forms, they are linked to chronic, life-threatening, and life-impairing diseases with substantial health risks that can result in death or disability. Unfortunately, due to a lack of knowledge, comprehensive programs, and organized preventative measures, a significant percentage of children worldwide are born with and suffer from these conditions. According to BGI Genomics Global 2023, 5.2% of people worldwide have hemoglobin abnormalities, which causes 300,000 to 400,000 babies to be born with severe hemoglobinopathies every year. In addition, 4.4 out of every 10,000 live births is affected with thalassemia, a hereditary hemoglobinopathy that is most common in Mediterranean coastal regions, Africa, the Middle East, Southeast Asia, and southern China. Roughly 80% of cases of thalassemia take place in low- and middle-income nations, where patients' quality of life is more likely to be in danger due to unequal access to medical care. Programs to control thalassemia must include genetic counselling, screening, public awareness, and prenatal diagnosis. Considering the magnitude of the problem and the cost implications of management, suitable control measures need to be undertaken immediately.

Hemoglobinopathies Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.5% over the forecast period (2023-2030)

Based on type segmentation, the Sickle Cell Disease segment is expected to dominate the market over the forecast period

Based on region, North America is expected to dominate the market during the forecast period

Hemoglobinopathies Market- Segmentation Analysis:

The Global Hemoglobinopathies Market is segmented based on Type, Therapy, Distribution Channel, and Region.

Based on the type, the global market is categorized into Sickle Cell Disease, Thalassemia and Others. The Sickle Cell Disease segment is expected to dominate the market over the forecast period. The market for sickle cell disease diagnostics has seen several notable developments recently. The creation and uptake of novel diagnostic technology is one such trend. Modern genetic testing techniques, including next-generation sequencing and molecular diagnostics, have made it possible to identify sickle cell disease and its variations more precisely and effectively. Rapid diagnostic kits and point-of-care testing (POCT) equipment have also been developed, making screening quick and easy in a variety of healthcare settings. For instance, Molbio Diagnostics and ShanMukha Innovations partnered in May 2023 to create, develop, and market affordable point-of-care diagnostic tools for the diagnosis of disorders associated with hemoglobinopathy.

Based on the therapy, the global hemoglobinopathies industry is divided into ACE inhibitors, Monoclonal Antibody Medication, Hydroxyurea and Others.

Based on the distribution channel, the market is bifurcated into Online Providers, Hospital Pharmacy, Drug Stores and Retail Pharmacy.

Hemoglobinopathies Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period because healthcare facilities are getting better and individuals are becoming more aware of hemoglobinopathies. Different groups run different activities to raise awareness. For instance, the United States national group SCDAA advocates for people with sickle cell disease and their families by raising awareness and providing support. To foster greater awareness and enhance the lives of individuals who suffer from the disease, they arrange events, offer resources, and give instructional materials. The region's market is expected to rise as a result of several programs launched by government agencies and research institutions to support the development of new treatments for hemoglobinopathies.

Hemoglobinopathies Market- Competitive Landscape:

To increase their market share, business leaders are launching several efforts, including partnerships, collaborations, mergers and acquisitions, and intensive R&D. The key players operating in the market are Novartis AG, Celgene Corporation, bluebird bio, Inc., Emmaus Life Sciences Inc., Pfizer, Inc., Sangamo Therapeutics, Inc., Prolong Pharmaceuticals, LLC, Global Blood Therapeutics, Inc., Gamida Cell and Bioverativ Inc.

Recent Developments:

In August 2023, the FDA in the United States released the clinical hold on the Investigational New Drug (IND) application for FTX-6058, which could be used to treat sickle-cell disease (SCD). Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that prioritizes improving the lives of patients with genetically defined rare diseases.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HEMOGLOBINOPATHIES MARKET KEY PLAYERS

  • Novartis AG
  • Celgene Corporation
  • bluebird bio, Inc.
  • Emmaus Life Sciences Inc.
  • Pfizer, Inc.
  • Sangamo Therapeutics, Inc.
  • Prolong Pharmaceuticals, LLC
  • Global Blood Therapeutics, Inc.
  • Gamida Cell
  • Bioverativ Inc.

GLOBAL HEMOGLOBINOPATHIES MARKET, BY TYPE

  • Sickle Cell Disease
  • Thalassemia
  • Others

GLOBAL HEMOGLOBINOPATHIES MARKET, BY THERAPY

  • ACE inhibitors
  • Monoclonal Antibody Medication
  • Hydroxyurea
  • Others

GLOBAL HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL

  • Online Providers
  • Hospital Pharmacy
  • Drug Stores
  • Retail Pharmacy

GLOBAL HEMOGLOBINOPATHIES MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Hemoglobinopathies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Hemoglobinopathies Market Snippet by Type
    • 2.1.2. Hemoglobinopathies Market Snippet by Therapy
    • 2.1.3. Hemoglobinopathies Market Snippet by Distribution Channel
    • 2.1.4. Hemoglobinopathies Market Snippet by Country
    • 2.1.5. Hemoglobinopathies Market Snippet by Region
  • 2.2. Competitive Insights

3. Hemoglobinopathies Key Market Trends

  • 3.1. Hemoglobinopathies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Hemoglobinopathies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Hemoglobinopathies Market Opportunities
  • 3.4. Hemoglobinopathies Market Future Trends

4. Hemoglobinopathies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Hemoglobinopathies Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Hemoglobinopathies Market Landscape

  • 6.1. Hemoglobinopathies Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Hemoglobinopathies Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
    • 7.1.2. Sickle Cell Disease
    • 7.1.3. Thalassemia
    • 7.1.4. Others

8. Hemoglobinopathies Market - By Therapy

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapy, 2022 & 2030 (%)
    • 8.1.2. ACE inhibitors
    • 8.1.3. Monoclonal Antibody Medication
    • 8.1.4. Hydroxyurea
    • 8.1.5. Others

9. Hemoglobinopathies Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Online Providers
    • 9.1.3. Hospital Pharmacy
    • 9.1.4. Drug Stores
    • 9.1.5. Retail Pharmacy

10. Hemoglobinopathies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Hemoglobinopathies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Hemoglobinopathies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Hemoglobinopathies Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Hemoglobinopathies Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Hemoglobinopathies Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Hemoglobinopathies Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
    • 11.2.2. Celgene Corporation
    • 11.2.3. bluebird bio, Inc.
    • 11.2.4. Emmaus Life Sciences Inc.
    • 11.2.5. Pfizer, Inc.
    • 11.2.6. Sangamo Therapeutics, Inc.
    • 11.2.7. Prolong Pharmaceuticals, LLC
    • 11.2.8. Global Blood Therapeutics, Inc.
    • 11.2.9. Gamida Cell
    • 11.2.10. Bioverativ Inc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Hemoglobinopathies Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Hemoglobinopathies Market, by Type 2018-2030 (USD Million)
  • TABLE Hemoglobinopathies Market: Therapy Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Therapy
  • TABLE Global Hemoglobinopathies Market, by Therapy 2018-2030 (USD Million)
  • TABLE Hemoglobinopathies Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Hemoglobinopathies Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Hemoglobinopathies Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Hemoglobinopathies Market, by Region 2018-2030 (USD Million)
  • TABLE North America Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE North America Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE Europe Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE Asia Pacific Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE Latin America Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Hemoglobinopathies Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Hemoglobinopathies Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Hemoglobinopathies Market, by Therapy, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Hemoglobinopathies Market, by Distribution Channel, 2018-2030 (USD Million)